Skip to main content
. 2020 Nov 26;6(1):100623. doi: 10.1016/j.adro.2020.11.008

Table 1.

Patient characeeristics and flare reactions

Patient no./age/sex Primary site Prior therapy Flare type (CTCAE score) Mitigation success
1/69/f Sm bowel SSA, temozolomide Cranial nerve dysfunction (2) Fair
2/46/f Sm bowel SSA, pall RT Bone pain (2) Good
3/68/m Pancreas SSA, everolimus, Y90 and chemo emb
4/57/f Sm bowel SSA
5/68/f Sm bowel SSA, bland and Y90 emb Epigastric pain (2) Fair
6/56/m Sm bowel SSA, TACE Small bowel dysfunction (2) Fair
7/47/f Sm bowel SSA pSBO (3) Good
8/65/f Kidney SSA
9/68/m Sm bowel SSA, Y90
10/77/f Sm bowel SSA, TACE, ablation. Liver resection
11/73/f Sm bowel SSA, TACE, everolimus, Y90
12/45/m Pancreas SSA, everolimus

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; emb = embolization; pall = palliative; pSBO = partial small bowel obstruction; RT = radiation therapy; sm = small; SSA = somatostatin analog therapy; TACE = transarterial chemoembolization.